Poloxamer-188 Adjuvant Efficiently Maintains Adaptive Immunity of SARS-CoV-2 RBD Subunit Vaccination through Repressing p38MAPK Signaling

Poloxamer-188 (P188) is a nonionic triblock linear copolymer that can be used as a pharmaceutical excipient because of its amphiphilic nature. This study investigated whether P188 can act as an adjuvant to improve the immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rec...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2022-05, Vol.10 (5), p.715
Main Authors: Chen, Chao-Hung, Lin, Yu-Jen, Cheng, Li-Ting, Lin, Chien-Hung, Ke, Guan-Ming
Format: Article
Language:English
Subjects:
Adaptive immunity
Antibodies
Antigens
Apoptosis
Biotechnology
Cell-mediated immunity
Copolymers
Coronaviruses
COVID-19
COVID-19 vaccines
Cytokines
Enzymes
Fibrosis
Helper cells
Humoral immunity
Immune response
Immune response (humoral)
Immune system
Immunity
Immunogenicity
Kidneys
Kinases
Lymphocytes T
Medical research
mRNA vaccines
p38MAPK
Phosphorylation
poloxamer 188
Poloxamers
Proteins
Research centers
SARS-CoV-2 vaccine
Severe acute respiratory syndrome coronavirus 2
Software
Statistical analysis
Vaccination
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Poloxamer-188 (P188) is a nonionic triblock linear copolymer that can be used as a pharmaceutical excipient because of its amphiphilic nature. This study investigated whether P188 can act as an adjuvant to improve the immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor binding domain (RBD) subunit vaccine. BALB/c mice were vaccinated twice with the RBD antigen alone or in combination with P188 or MF59 (a commercial adjuvant for comparison purposes). The resulting humoral and cellular immunity were assessed. Results showed that P188 helped elicit higher neutralizing activity than MF59 after vaccination. P188 induced significant humoral immune response, along with type 1 T helper (Th1) and type 2 T helper (Th2) cellular immune response when compared with MF59 due to repressing p38MAPK phosphorylation. Furthermore, P188 did not result in adverse effects such as fibrosis of liver or kidney after vaccination. In conclusion, P188 is a novel adjuvant that may be used for safe and effective immune enhancement of the SARS-CoV-2 RBD antigen.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines10050715